Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.
Tesla delivers record Q3 vehicles, but misses earnings expectations as higher costs and declining regulatory credits weigh on margins.
Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.
Tesla delivers record Q3 vehicles, but misses earnings expectations as higher costs and declining regulatory credits weigh on margins.